The University of Southampton
University of Southampton Institutional Repository

Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR study

Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR study
Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR study
The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 months. The current study investigated the impact of treatment with ranibizumab as needed (pro re nata [PRN]) on individuals with myopic choroidal neovascularization (mCNV) in the REPAIR study, using patient-reported outcome measures (PROMs) for treatment satisfaction and well-being. This study included 65 adults with mCNV and a best-corrected visual acuity (BCVA) letter score of 24-78 in the study eye. Patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) at months 1, 6 and 12, and the 12-item Well-Being Questionnaire (W-BQ12) at baseline and months 1, 6 and 12. Subgroup analyses investigated the relationship between PROM scores and treatment in the better- or worse-seeing eye (BSE/WSE), number of injections received, baseline BCVA, BCVA improvement and age. Pearson correlations between change in BCVA, MacTSQ scores and W-BQ12 scores were calculated. The main outcome measures were treatment satisfaction measured with the MacTSQ (score 0-72) and well-being measured with the W-BQ12 (score 0-36). Treatment satisfaction significantly increased over the study period (p = 0.0001). Mean MacTSQ scores increased by 9.7 and 10.0 in patients treated in their WSE and BSE, respectively. Treatment satisfaction was highest in individuals receiving only one injection at month 1; however, by month 12, scores were similar across injection subgroups. Patients aged 68 years or older had the highest MacTSQ scores. Well-being scores also significantly increased over the study period (p = 0.03). Mean W-BQ12 scores increased by 1.7 in patients treated in their WSE and by 2.1 in patients treated in their BSE. Individuals aged 40 years or younger had the greatest increases in general well-being. Patients who experienced stable or improved BCVA at month 12 had greater increases in W-BQ12 scores than those who experienced a decrease. Correlations between BCVA, MacTSQ scores and W-BQ12 scores were largely non-significant. In conclusion, treatment satisfaction and well-being increased during treatment with ranibizumab PRN. Although directly comparable data are limited for the MacTSQ and W-BQ12 in mCNV, these results complement PROM outcomes reported in related studies.
1932-6203
1-13
Amoaku, Winfried M.
f5d6a832-cfea-42fb-bb6c-0eaf0ac00828
Gale, Richard P.
32d42683-5d9e-4a4e-808f-e971fe807ebc
Lotery, Andrew J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Menon, Geeta
941f77e0-5d93-49a8-ac38-a250c4bdbc06
Sivaprasad, Sobha
7cd590d6-18f0-4ae1-8ace-4b35833c2f03
Petrillo, Jennifer
2c5bea3c-e4fc-4fa8-8e22-9cb2d76ccbb9
Quinn, Jennifer
5319b29f-1be5-42f5-b3fd-95b029e7b14e
Amoaku, Winfried M.
f5d6a832-cfea-42fb-bb6c-0eaf0ac00828
Gale, Richard P.
32d42683-5d9e-4a4e-808f-e971fe807ebc
Lotery, Andrew J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Menon, Geeta
941f77e0-5d93-49a8-ac38-a250c4bdbc06
Sivaprasad, Sobha
7cd590d6-18f0-4ae1-8ace-4b35833c2f03
Petrillo, Jennifer
2c5bea3c-e4fc-4fa8-8e22-9cb2d76ccbb9
Quinn, Jennifer
5319b29f-1be5-42f5-b3fd-95b029e7b14e

Amoaku, Winfried M., Gale, Richard P., Lotery, Andrew J., Menon, Geeta, Sivaprasad, Sobha, Petrillo, Jennifer and Quinn, Jennifer (2015) Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR study. PLoS ONE, 10 (6), 1-13. (doi:10.1371/journal.pone.0128403). (PMID:26039355)

Record type: Article

Abstract

The Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen (REPAIR) trial was a prospective study exploring the efficacy and safety of intravitreal ranibizumab 0.5 mg using an individualized treatment regimen over 12 months. The current study investigated the impact of treatment with ranibizumab as needed (pro re nata [PRN]) on individuals with myopic choroidal neovascularization (mCNV) in the REPAIR study, using patient-reported outcome measures (PROMs) for treatment satisfaction and well-being. This study included 65 adults with mCNV and a best-corrected visual acuity (BCVA) letter score of 24-78 in the study eye. Patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) at months 1, 6 and 12, and the 12-item Well-Being Questionnaire (W-BQ12) at baseline and months 1, 6 and 12. Subgroup analyses investigated the relationship between PROM scores and treatment in the better- or worse-seeing eye (BSE/WSE), number of injections received, baseline BCVA, BCVA improvement and age. Pearson correlations between change in BCVA, MacTSQ scores and W-BQ12 scores were calculated. The main outcome measures were treatment satisfaction measured with the MacTSQ (score 0-72) and well-being measured with the W-BQ12 (score 0-36). Treatment satisfaction significantly increased over the study period (p = 0.0001). Mean MacTSQ scores increased by 9.7 and 10.0 in patients treated in their WSE and BSE, respectively. Treatment satisfaction was highest in individuals receiving only one injection at month 1; however, by month 12, scores were similar across injection subgroups. Patients aged 68 years or older had the highest MacTSQ scores. Well-being scores also significantly increased over the study period (p = 0.03). Mean W-BQ12 scores increased by 1.7 in patients treated in their WSE and by 2.1 in patients treated in their BSE. Individuals aged 40 years or younger had the greatest increases in general well-being. Patients who experienced stable or improved BCVA at month 12 had greater increases in W-BQ12 scores than those who experienced a decrease. Correlations between BCVA, MacTSQ scores and W-BQ12 scores were largely non-significant. In conclusion, treatment satisfaction and well-being increased during treatment with ranibizumab PRN. Although directly comparable data are limited for the MacTSQ and W-BQ12 in mCNV, these results complement PROM outcomes reported in related studies.

PDF
journal.pone.0128403.PDF - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 23 April 2015
Published date: 3 June 2015
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 390414
URI: https://eprints.soton.ac.uk/id/eprint/390414
ISSN: 1932-6203
PURE UUID: 7841df0b-84d4-4572-8f68-fd0a1a57d717
ORCID for Andrew J. Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 01 Apr 2016 11:18
Last modified: 31 Jan 2019 01:36

Export record

Altmetrics

Contributors

Author: Winfried M. Amoaku
Author: Richard P. Gale
Author: Geeta Menon
Author: Sobha Sivaprasad
Author: Jennifer Petrillo
Author: Jennifer Quinn

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×